Researchers of VTT and the University of Turku discover new information on cancer generation mechanisms
A cell that is ‘adrift’ is not able to divide normally
For decades, researchers have known that human cells must be in their right place in the body, surrounded by tissue, in order for them to be able to divide normally. When separated from the rest of the tissue, normal cells are not able to divide and will thus die.
Microscopic images taken by the group’s doctoral researchers, Saara Tuomi and Teijo Pellinen, revealed that a dividing cell anchors itself during the various stages of division by using cell adhesion receptors called integrins. A cell with malfunctioning anchoring molecules will become adrift and start to divide abnormally and thus acquire the potential to become a cancer cell. The research group also uncovered evidence, in cooperation with a research group led by professor Olli Kallioniemi, that the anchoring mechanism had been disturbed in some cases of ovarian cancer and in some prostate cancer metastases. The finding supports the hypothesis proposed by scientists at the beginning of the last century that abnormal cell division is one of the mechanisms in the development of cancer.
The research results open an entirely new perspective on the early stages of the development of cancer and how the changes occurring in cancerous tissue enable the cancer to continuously become a more malignant and more aggressive tumour. When cells become independent of their anchoring mechanisms, a vicious circle is created: genotype changes occurring at an ever-increasing pace enable the disease to become more and more aggressive.
Original publication: Pellinen T., Tuomi S., Arjonen A., Wolf M., Edgren H., Meyer H., Grosse R., Kitzing T., Rantala JK., Kallioniemi O., Fässler R., Kallio M., and Ivaska J.; "Integrin traffic regulated by Rab21 is necessary for cytokinesis."; Developmental Cell 2008.
Most read news
Organizations
Other news from the department science
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.